Your session is about to expire
← Back to Search
Alpha-2 Adrenergic Agonist
Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation for Red Eye
Phase 3
Waitlist Available
Research Sponsored by Bausch & Lomb Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 hours after instillation
Awards & highlights
Study Summary
This trial will compare the efficacy and safety of two eye drops for people with ocular redness.
Eligible Conditions
- Red Eye
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 hours after instillation
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 hours after instillation
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Ocular redness
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Brimonidine tartrate preservation-freeExperimental Treatment1 Intervention
Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
Group II: Lumify®Active Control1 Intervention
Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Brimonidine
FDA approved
Find a Location
Who is running the clinical trial?
Bausch & Lomb IncorporatedLead Sponsor
251 Previous Clinical Trials
57,036 Total Patients Enrolled
Daniel DonatelloStudy DirectorBausch & Lomb Incorporated
4 Previous Clinical Trials
1,590 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have used redness relief eye drops in the past 6 months or you want to use over-the-counter eye drops for redness relief.
Research Study Groups:
This trial has the following groups:- Group 1: Brimonidine tartrate preservation-free
- Group 2: Lumify®
Awards:
This trial has 4 awards, including:- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any side-effects to using Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation?
"There is already some efficacy data and multiple rounds of safety data for Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation, so it was given a score of 3."
Answered by AI
Could you inform me as to how many facilities are testing this procedure?
"There are a total of 6 sites that are running this clinical trial. The locations are based in Memphis, Clinton and Shelby. To help with the burden of travel, please enroll at the nearest location to you."
Answered by AI
Who else is applying?
What portion of applicants met pre-screening criteria?
Did not meet criteria
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger